Browse by Audience
Skip to content
Papers of the Week
The safety of COVID-19 vaccination in immunocompromised children and young adults with immune-mediated inflammatory disease.
Abstract
To assess safety of COVID-19 vaccination in pediatric patients with immune-mediated inflammatory disease (IMID) METHODS: Subjects 5-21 years of age with IMID who received at least one COVID-19 vaccine completed electronic surveys after each vaccine to assess side effects within one week of vaccination, current medications, and COVID-19 testing after vaccination. Charts were reviewed for COVID-19 polymerase chain reaction and IgG response to SARS-CoV-2 spike protein results, and for disease flare during the study period.